Stock Events

Stock Events

PepGen 

$3.11
19
-$0.07-2.2% Friday 19:59
-$0.01-0.26%Friday 21:24After hours

Statistics

Day High
3.11
Day Low
3.1
52W High
7.8
52W Low
1.3
Volume
3,272
Avg. Volume
-
Mkt Cap
215.4M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.92
-0.7
-0.48
-0.26
Expected EPS
-0.265663
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-89.66MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 11.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PEPG. It's not an investment recommendation.
Apple
3
AAPL
Micron Technology
3
MU
Strategy
3
MSTR
Coinbase Global
3
COIN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, similar to PepGen's focus on Duchenne muscular dystrophy and myotonic dystrophy.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics is involved in the development of genetically targeted therapies for the treatment of rare disorders, competing in the same therapeutic areas as PepGen.
Silence Therapeutics
SLN
Mkt Cap834.11M
Silence Therapeutics develops RNA interference (RNAi) therapies for the treatment of diseases with significant unmet medical need, overlapping with PepGen's RNA platform.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, directly competing with PepGen's approach to treating genetic disorders.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA space with PepGen.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other drug development for rare genetic diseases, competing in similar markets as PepGen.
Dyadic International DE
DYAI
Mkt Cap24.6M
Dyadic International, Inc. works on developing and licensing its proprietary C1 gene expression platform for biopharmaceutical drug development, potentially competing in the production of therapies similar to those of PepGen.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.52B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with a focus on serious, debilitating genetic diseases, including therapies that could compete with PepGen's products.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on the development of gene-based therapies using CRISPR/Cas9 technology, which could be applied to similar diseases as those targeted by PepGen.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine works on editing genes to treat a broad range of diseases, including those in PepGen's focus area, making it a competitor in the gene therapy space.

About

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Show more...
CEO
James McArthur
Employees
57
Country
United States
ISIN
US7133171055

Listings

XNAS
US
PEPG
BOATS
BOATS
PEPG.BOATS

0 Comments

Share your thoughts

FAQ

What is PepGen stock price today?▼
The current price of PEPG is $3.11 USD — it has decreased by -2.2% in the past 24 hours. Watch PepGen stock price performance more closely on the chart.
What is PepGen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange PepGen stocks are traded under the ticker PEPG.
Is PepGen stock price growing?▼
PEPG stock has risen by +0.97% compared to the previous week, the month change is a +57.07% rise, over the last year PepGen has showed a +122.14% increase.
What is PepGen market cap?▼
Today PepGen has the market capitalization of 215.4M
When is the next PepGen earnings date?▼
PepGen is going to release the next earnings report on November 11, 2026.
What were PepGen earnings last quarter?▼
PEPG earnings for the last quarter are -0.26 USD per share, whereas the estimation was -0.28 USD resulting in a +8.6% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PepGen revenue for the last year?▼
PepGen revenue for the last year amounts to 0 USD.
What is PepGen net income for the last year?▼
PEPG net income for the last year is -89.66M USD.
How many employees does PepGen have?▼
As of September 05, 2026, the company has 57 employees.
In which sector is PepGen located?▼
PepGen operates in the Health & Wellness sector.
When did PepGen complete a stock split?▼
PepGen has not had any recent stock splits.
Where is PepGen headquartered?▼
PepGen is headquartered in BOSTON, United States.